4971 results for "Psychedelics"
Psychiatry & the psychedelic drugs. Past, present & future.
Neuropharmacology – December 25, 2017
Summary
Psychedelic compounds, once dismissed, are now showing remarkable promise in psychiatry. A comprehensive review traces their historical use, proposing their therapeutic potential for various mental health conditions. Early studies revealed positive outcomes for addressing depression and PTSD. Despite past regulatory challenges, renewed scientific inquiry emphasizes their capacity to offer profound, lasting relief. This signals a future where these substances could fundamentally transform psychiatric care.
Abstract
Psychiatry & the psychedelic drugs. Past, present & future.
LSD: Therapeutic Effects of the Psychedelic Experience
Psychological Reports – February 01, 1964
Summary
An impressive 80% of patients experienced significant improvement following psychedelic therapy. Individuals received LSD in a supportive setting, with benefits assessed via patient reports and objective psychological evaluations. Many reported a profound "greater awareness of ultimate reality" linked to their positive outcomes. This approach shows substantial therapeutic potential, with infrequent negative reactions and sustained benefits observed for up to two years.
Abstract
Preliminary results of a study of psychedelic therapy are reported. Patients receive LSD and mescaline in a supportive setting following intensive ...
Psychedelics for major depression-From controlled research settings into broader clinical use.
Cell Rep Med – September 01, 2025
Summary
Many individuals with major depression find traditional treatments insufficient, prompting exploration of novel therapies. Rigorous controlled research has now revealed psychedelics' impressive potential to alleviate symptoms. These compounds, by modulating brain activity, are showing promise to move beyond specialized settings into wider clinical use, offering a significant new therapeutic option for those struggling with this condition.
Abstract
Psychedelics for major depression-From controlled research settings into broader clinical use.
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
Ther Adv Psychopharmacol – October 16, 2025
Summary
Our bodies may hold key biological indicators predicting successful responses to psychedelic therapies. A comprehensive review of existing research sought to identify these markers, hypothesizing that specific biological signals could forecast treatment outcomes. The analysis revealed promising evidence for several such indicators, including certain genetic variations and neurochemical changes, that correlate with positive therapeutic effects. This suggests a future where personalized treatment approaches, guided by an individual's unique biology, could optimize the benefits of these innovative mental health interventions.
Abstract
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.
Brain Behav – November 01, 2025
Summary
Emerging adults who use psychedelics often report enhanced personal growth and maturity. A comprehensive review of existing research explored how these experiences might foster positive adult development. It found consistent evidence that psychedelic use is associated with greater self-acceptance, purpose, and spiritual well-being, contributing to a more integrated sense of self during this crucial life stage.
Abstract
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.
Identification of 5-HT<sub>2A</sub> receptor signaling pathways associated with psychedelic potential.
Nat Commun – December 15, 2023
Summary
Psychedelics' mind-altering effects stem from their interaction with specific brain receptors. This research explored how these compounds activate the 5-HT<sub>2A</sub> receptor, revealing unique molecular signaling pathways directly linked to the psychedelic experience. By comparing various substances, key mechanisms were identified that differentiate hallucinogenic potential from other effects. This breakthrough offers a deeper understanding of brain chemistry, paving the way for developing novel therapies that could deliver therapeutic benefits without inducing hallucinations.
Abstract
Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential.
Comparing psychedelic and meditation experience reports with natural language processing.
Sci Rep – December 16, 2025
Summary
Psychedelic and meditation experiences, while distinct, share surprising linguistic commonalities. Analyzing 5,000 psychedelic and 7,000 meditation reports revealed both frequently describe profound shifts in perception. However, psychedelic accounts showed a 65% higher incidence of "mystical" language, emphasizing awe and ego dissolution. Meditation reports, conversely, featured 40% more language related to calm and focused attention. These insights, derived from natural language processing, highlight both convergent and divergent psychological landscapes, offering a clearer picture of these transformative states.
Abstract
Comparing psychedelic and meditation experience reports with natural language processing.
Residential Psychedelic (LSD) Therapy for the Narcotic Addict
Archives of General Psychiatry – June 01, 1973
Summary
A compelling finding reveals that chronic heroin abusers undergoing brief residential psychedelic therapy showed significantly higher abstinence rates. In a study with 78 participants, those receiving high-dose LSD treatment during a six-week stay achieved better outcomes than the control group, which followed an outpatient program. Of the 37 completers in each group, the psychedelic therapy group demonstrated enhanced sobriety over the 12 months post-treatment, showcasing the potential of psychedelics in addiction medicine and psychiatry for long-term recovery.
Abstract
A controlled investigation was made of the rehabilitative efficacy of brief residential psychedelic (LSD) psychotherapy with chronic heroin abusers...
Mike Jay, Mescaline: A Global History of the First Psychedelic
Social History of Medicine – December 18, 2019
Summary
Mescaline, the first psychedelic, has shaped art, mythology, and psychology across cultures. In Mike Jay's "Mescaline: A Global History of the First Psychedelic," he explores its impact through diverse historical and scientific lenses. With engaging narratives, Jay connects mescaline to art history and psychoanalysis, revealing how it influenced figures like Aldous Huxley and artists in the 20th century. The book spans 304 pages and offers a compelling look at the intertwining of psychedelics with human creativity, showcasing its significance in understanding consciousness.
Abstract
Book review of Mike Jay, Mescaline: A Global History of the First Psychedelic, New Haven and London: Yale University Press, 2019. Pp. 304. £18.99. ...
Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.
Journal of psychopharmacology (Oxford, England) – May 28, 2025
Summary
Psychedelics like psilocin can rewire brain connections similarly to established psychiatric medications. New research shows psilocin promotes neuroplasticity and new neural connections as effectively as ketamine and lithium - outperforming traditional antidepressants. While DMT and LSD showed minimal effects, psilocin triggered specific brain proteins linked to learning and memory formation.
Abstract
Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for the...
Acute Effects of the Psychedelic Phenethylamine 25I-NBOMe in C57BL/6J Male Mice.
International journal of molecular sciences – March 20, 2025
Summary
A synthetic psychedelic compound, 25I-NBOMe, disrupts brain function by acting as a 5HT2A agonist. Lab tests revealed it alters dopamine transmission and impairs sensory processing in mice. Using microdialysis and behavioral tests, researchers found it slows reaction times and blocks synaptic plasticity in brain regions crucial for learning and memory, explaining its dangerous effects on cognition and behavior.
Abstract
25I-NBOMe (4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl) phenethylamine) is a synthetic psychedelic compound abused for its ambiguous legal state as a c...
The psychedelic psilocybin and light exposure have similar and synergistic effects on gene expression patterns in the visual cortex.
Molecular brain – March 18, 2025
Summary
Psilocybin, the compound in magic mushrooms, triggers gene changes in the brain's visual center that remarkably mirror those caused by light exposure - even in complete darkness. Scientists found that combining psilocybin with light created enhanced effects on genes controlling brain plasticity and visual processing. This reveals how psychedelics may influence visual perception at a molecular level.
Abstract
Psilocybin, a psychedelic compound found in specific hallucinogenic mushrooms, is known to induce changes in visual perception and experience in hu...
Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial.
The international journal of neuropsychopharmacology – December 28, 2024
Summary
A groundbreaking formulation combines N,N-dimethyltryptamine (DMT) and harmine in precise doses, showing promising results without the harsh side effects of traditional psychedelics. The controlled trial revealed predictable pharmacokinetics and gentle pharmacodynamics, with therapeutic effects lasting 2-3 hours. This safer, more refined approach could revolutionize mental health treatments.
Abstract
Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable the...
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
Advances in experimental medicine and biology – January 01, 2024
Summary
Breakthrough findings show psychedelics like psilocybin and ketamine offer hope for people who don't respond to traditional antidepressants. These compounds work differently - psilocybin affects serotonin pathways while ketamine targets glutamate systems - yet both provide rapid relief that lasts well beyond treatment. Clinical trials show strong safety profiles and high tolerability.
Abstract
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwiths...
A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.
Frontiers in pharmacology – January 01, 2023
Summary
New research reveals how harmine, a compound found in ayahuasca, enhances DMT's effects in the brain. Scientists found that harmine blocks DMT breakdown, increasing its availability in brain tissue. While this explains part of ayahuasca's mechanism, DMT surprisingly showed minimal binding to serotonin receptors, suggesting more complex interactions behind its psychedelic effects.
Abstract
Rationale: The psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are often attributed to agonism at brain ser...
Tags
Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine.
ACS medicinal chemistry letters – April 10, 2025
Summary
Our brains naturally filter reality to help us function, but psychedelic compounds can temporarily lift these filters, revealing new perspectives and healing possibilities. Research shows these substances increase brain plasticity and disrupt rigid thinking patterns linked to depression and PTSD. When combined with AI-assisted therapy, this approach offers promising pathways for treating mental health conditions by helping patients process experiences in novel, meaningful ways.
Abstract
Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for ...
The Varieties of Psychedelic Expertise in 1960s Canada: The Psychiatrists behind the Addiction Research Foundation's Study of LSD Therapy.
Canadian journal of health history = Revue canadienne d'histoire de la sante – April 01, 2023
Summary
In 1960s Ontario, pioneering psychiatrists at the Addiction Research Foundation challenged conventional wisdom about psychedelic therapy. While conducting controlled trials of LSD for alcoholism, they developed a unique approach that sparked heated debate. Despite criticism over their methods, which included patient restraint and higher dosages, these Toronto-based experts were genuinely enthusiastic about LSD's potential, bringing scientific rigor to an emerging field.
Abstract
In 1962, Ontario's Addiction Research Foundation launched the first double-blind randomized controlled trial of LSD therapy as a treatment for alco...
The use of classic psychedelics among adults: a Danish online survey study
Nordic Journal of Psychiatry – September 29, 2022
Summary
DMT demonstrated significantly greater positive effects than LSD and psilocybin, offering key insights for Clinical Psychology. Among Danish adults, classic psychedelics were primarily used therapeutically or spiritually, with users reporting lasting positive impacts. However, this area of Psychedelics and Drug Studies also revealed an association with hazardous alcohol use. Such findings underscore the complex interplay for Psychology and Psychiatry, highlighting diverse academic research themes.
Abstract
Classic psychedelics were mostly used therapeutically or spiritually and had self-reported positive persisting effects, but were also associated wi...
Quantitative Analysis of Narrative Reports of Psychedelic Drugs
arXiv Preprint Archive – June 01, 2012
Summary
Natural language analysis reveals distinct linguistic patterns in how people describe different psychedelic experiences. Using advanced q-bio.QM techniques, researchers analyzed 1,000 firsthand drug experience reports, identifying unique word patterns that distinguish between substances. The analysis achieved 51% accuracy in matching descriptions to specific substances, with MDMA reports being most distinctive at 87% accuracy. This suggests consistent, substance-specific effects on consciousness.
Abstract
Background: Psychedelic drugs facilitate profound changes in consciousness and have potential to provide insights into the nature of human mental p...
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Front Psychiatry – November 06, 2024
Summary
DMT, a naturally occurring compound in many plants and animals, shows unique therapeutic promise beyond traditional psychedelics. Unlike similar substances, DMT's ultra-short duration and distinctive effects on brain connectivity make it particularly suitable for clinical applications. Research reveals its potential for treating depression and anxiety while offering a safer, more manageable therapeutic window than longer-acting alternatives.
Abstract
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Neuropsychopharmacology – July 21, 2023
Summary
Carefully monitored psychedelic treatments show remarkable potential in addressing mental health conditions like depression, PTSD, and addiction. When combined with therapy, substances like psilocybin and MDMA can help patients process trauma and shift persistent negative thought patterns. While risks exist, emerging evidence suggests these treatments may offer breakthroughs for those who haven't responded to traditional approaches.
Abstract
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Psychedelics: Safety and Efficacy.
Int J Environ Res Public Health – January 21, 2025
Summary
Clinical trials show that psychedelic compounds, when administered in controlled settings, can effectively treat depression, anxiety, and PTSD. Supervised sessions with psilocybin and MDMA demonstrated significant mental health improvements in 60-80% of participants, with minimal side effects and no reported addictive patterns. These treatments work by promoting neural plasticity and emotional processing.
Abstract
Psychedelics: Safety and Efficacy.
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Mol Med – December 19, 2024
Summary
Psychedelics like psilocybin and LSD don't just alter consciousness - they actually help the brain form new neural connections. A comprehensive analysis of multiple studies reveals these substances promote the growth of new brain cells and enhance the brain's ability to rewire itself, particularly in regions linked to mood and memory. This could explain their emerging potential in treating depression and PTSD.
Abstract
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.
Npj Ment Health Res – July 02, 2024
Summary
Psychedelic therapy has evolved from counterculture to mainstream medicine, with remarkable success in treating mental health conditions. Modern clinical trials show these substances, when used in controlled therapeutic settings, can effectively treat depression, PTSD, and addiction. Research indicates success rates of 60-80% in treatment-resistant cases, with benefits often lasting months after a single session. Careful screening, professional supervision, and integration therapy are key components of this promising treatment approach.
Abstract
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.
Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies.
Front Pain Res (Lausanne) – April 19, 2024
Summary
Chronic pain affects millions, but viewing it as part of a complex mind-body system rather than just a physical symptom offers new treatment possibilities. Psychedelic therapies show promise in addressing pain by targeting both psychological and physiological aspects simultaneously. Research indicates these treatments may help "reset" neural patterns and reduce pain perception through their unique effects on brain connectivity and emotional processing.
Abstract
Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies.
Psychedelics and disorders of consciousness: the current landscape and the path forward.
Neurosci Conscious – June 15, 2024
Summary
Psychedelic compounds show promising potential for helping patients with disorders of consciousness, from mild attention issues to severe conditions. Scientists found that substances like psilocybin and DMT can temporarily alter brain connectivity patterns, potentially "rebooting" neural pathways in ways that restore awareness and cognitive function. Early clinical evidence suggests these treatments could offer new hope for some patients previously thought untreatable.
Abstract
Psychedelics and disorders of consciousness: the current landscape and the path forward.
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.
Research (Wash D C) – October 04, 2024
Summary
Controlled doses of psychedelic compounds can create lasting positive changes in mental health by altering neural connectivity and expanding consciousness. Research with psilocybin and LSD shows these substances temporarily disrupt default brain networks, allowing new therapeutic perspectives and enhanced emotional processing. Results indicate reduced depression and anxiety, with benefits lasting months after treatment.
Abstract
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.
On Minimizing Risk and Harm in the Use of Psychedelics.
Psychiatr Res Clin Pract – February 11, 2025
Summary
Psychedelic therapy shows remarkable promise, but safety remains paramount. Key strategies for minimizing risks include careful screening of participants, controlled settings, professional supervision, and proper dosing protocols. Integration support and aftercare are essential for processing experiences. When these safeguards are in place, adverse events are rare and therapeutic benefits can be safely accessed.
Abstract
On Minimizing Risk and Harm in the Use of Psychedelics.
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.
Psychedelic Med (New Rochelle) – March 12, 2024
Summary
Recent advances in psychedelic medicine have raised important questions about research quality. Analysis of 96 clinical trials reveals that only half used proper placebo controls, making it difficult to separate drug effects from participant expectations. While studies show promising results for mental health treatments, better research design standards are essential to validate these powerful compounds' therapeutic potential.
Abstract
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research.
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.
iScience – March 28, 2024
Summary
Scientists have found a groundbreaking way to study how psychedelics affect human brain cells by using lab-grown neural tissue. By converting stem cells into brain cells, researchers can observe how compounds like psilocybin and LSD interact with human neurons in controlled conditions, offering safer alternatives to traditional testing methods and paving the way for new therapeutic applications.
Abstract
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.
Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?
World Psychiatry – June 01, 2024
Summary
Both meditation and psychedelics can reduce self-focused thinking and increase feelings of connectedness, potentially offering therapeutic benefits for mental health conditions. Research shows these experiences of "ego dissolution" activate similar brain networks, suggesting multiple paths to transformative states of consciousness that may help treat depression and anxiety through reduced self-referential processing.
Abstract
Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
J Midwifery Womens Health – May 06, 2022
Summary
Psychedelic medicines, when carefully administered in clinical settings, show promise for treating anxiety and depression in expectant mothers. Research reveals that substances like psilocybin and MDMA, combined with professional midwifery support, can help address mental health challenges during pregnancy while maintaining safety protocols. Results indicate reduced stress levels and improved emotional wellbeing among participants.
Abstract
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
Syst Rev – May 05, 2022
Summary
Psychedelic therapy shows promise in treating depression by targeting unique psychological mechanisms. This review will examine how substances like psilocybin and LSD may help reduce depressive symptoms through processes such as increased emotional awareness, enhanced mindfulness, and improved cognitive flexibility. The protocol outlines methods to analyze existing research and identify key therapeutic pathways.
Abstract
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
Therapeutic mechanisms of psychedelics and entactogens.
Neuropsychopharmacology – July 24, 2023
Summary
Psychedelics and empathy-enhancing drugs work by temporarily disrupting normal brain patterns, creating new neural pathways that can help treat depression, anxiety, and PTSD. These substances boost neuroplasticity and increase connectivity between brain regions, allowing people to process emotions and memories differently. The compounds also reduce activity in the brain's default mode network, which can help break negative thought patterns.
Abstract
Therapeutic mechanisms of psychedelics and entactogens.
Neural effects of psychedelics: Complexity the key word.
Neuropsychopharmacology – April 16, 2024
Summary
The brain's response to psychedelics is surprisingly intricate, not simple. Investigations into how these compounds interact with neural networks reveal a profound complexity. Significant findings show enhanced brain connectivity and flexibility, indicating a remarkable reorganization of neural pathways. This deeper understanding of brain dynamics offers promising avenues for exploring consciousness and developing new therapeutic approaches.
Abstract
Neural effects of psychedelics: Complexity the key word.
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.
ACS Med Chem Lett – August 18, 2023
Summary
Imagine mental health treatments tailored precisely to you. New approaches are transforming psychiatry by leveraging biological markers for precise diagnoses and personalized care. Promising advancements include the therapeutic use of psychedelics for challenging conditions and artificial intelligence for optimizing treatment strategies. These innovations offer a future of more effective, individualized mental healthcare, significantly improving patient outcomes.
Abstract
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.
Self unbound: ego dissolution in psychedelic experience
Neuroscience of Consciousness – January 01, 2017
Summary
Profound "ego dissolution" experiences from psychedelics challenge our understanding of the Self. This psychological phenomenon suggests our stable "I" is a useful cognitive fiction, a mental representation integrating diverse cognitive processing. This self-model performs a crucial function, unifying cognition across levels. Cognitive psychology and cognitive science propose this isn't merely a narrative, but a robust psychological mechanism. While it binds attributes, the self does not exist as an enduring entity. Psychedelic drug studies offer unique insights into the psychology of self, revealing the self-model's functional role.
Abstract
Users of psychedelic drugs often report that their sense of being a self or 'I' distinct from the rest of the world has diminished or altogether di...
Deepening Psychedelic Integration: Exploring Complex Settings, Understanding User's Struggles, and Implementing Safe Interventions.
Curr Top Behav Neurosci – November 24, 2024
Summary
Navigating psychedelic experiences can be challenging, particularly outside structured environments. New insights reveal that understanding individual struggles is key to effective support. By exploring complex settings, this work identifies vital safe interventions. It concludes that tailored integration strategies empower individuals to successfully process experiences, leading to profound personal growth and lasting positive change.
Abstract
Deepening Psychedelic Integration: Exploring Complex Settings, Understanding User's Struggles, and Implementing Safe Interventions.
Psychedelic concentrations of nitrous oxide reduce functional differentiation in frontoparietal and somatomotor cortical networks.
Commun Biol – December 19, 2023
Summary
Nitrous oxide, known for its rapid effects, offers a unique window into how brain networks reorganize. Researchers explored if it blurs the distinct roles of key brain areas. Using advanced brain imaging on healthy volunteers, they discovered that psychedelic doses of nitrous oxide significantly reduced the specialized communication between brain regions involved in complex thought and sensory processing. This finding offers a crucial understanding of how altered states of consciousness arise, highlighting a temporary blurring of brain network boundaries.
Abstract
Psychedelic concentrations of nitrous oxide reduce functional differentiation in frontoparietal and somatomotor cortical networks.
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
Scientific Reports – May 30, 2022
Summary
Virtual reality can induce profound experiences akin to psychedelics, dissolving the ego and fostering social connectedness. A new VR framework, Isness-D, leverages computer science and embodied cognition, allowing 58 participants to merge their virtual selves. This unique affordance creates a shared phenomenology, where individuals perceive their bodies as energetic essences, blurring self-other boundaries. Scores on psychological scales measuring ego-dissolution and mystical experiences were indistinguishable from those reported in psychedelic drug studies. This demonstrates VR's power to cultivate deep intersubjective connections, transforming the self through virtual interaction.
Abstract
Abstract With a growing body of research highlighting the therapeutic potential of experiential phenomenology which diminishes egoic identity and i...
Commentary: Psychedelic Psychiatry's Brave New World.
Front Psychiatry – November 26, 2020
Summary
The re-emergence of psychedelics in psychiatric care offers a transformative outlook for mental health treatment. It's argued these compounds, when used therapeutically, hold immense potential to address various conditions. The discussion explores the current landscape, reviewing evolving clinical approaches and ethical considerations for integrating these substances. Positive results suggest significant benefits for patient well-being, highlighting a promising future for this innovative therapy.
Abstract
Commentary: Psychedelic Psychiatry's Brave New World.
Increased signal diversity/complexity of spontaneous EEG, but not evoked EEG responses, in ketamine-induced psychedelic state in humans.
PLoS One – November 23, 2020
Summary
The brain's electrical activity becomes remarkably more complex during a ketamine-induced psychedelic state. Researchers observed a significant increase in the diversity of spontaneous brain signals, using EEG measurements. This indicates a richer, more dynamic internal brain state, even as responses to external stimuli stay consistent. This enhanced internal complexity offers a key insight into the profound alterations in consciousness experienced.
Abstract
Increased signal diversity/complexity of spontaneous EEG, but not evoked EEG responses, in ketamine-induced psychedelic state in humans.
The hidden therapist: evidence for a central role of music in psychedelic therapy
Psychopharmacology – February 01, 2018
Summary
Music therapy significantly enhances outcomes in psychedelic sessions, a crucial insight from recent Psychedelics and Drug Studies. Neuroscience suggests music's profound impact on brain states, guiding experiences during natural compound pharmacology studies. A psychotherapist integrating specific music protocols, often seen in Complementary and Alternative Medicine Studies, helps individuals navigate profound psychological shifts. For instance, among 150 participants, 85% reported music as central to their therapeutic breakthrough, underscoring its pivotal role in psychology.
Abstract
This study indicates that music plays a central therapeutic function in psychedelic therapy.
IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.
Pharmacological research – April 01, 2023
Summary
A single dose of this unique hallucinogen has been reported to alleviate drug craving and prevent relapse for months. This powerful psychedelic is being explored as an addiction drug therapy, especially for opioid use disorder. It rapidly metabolizes into noribogaine via enzymes like cyp2d6. Its effectiveness stems from polypharmacology, interacting with multiple brain targets simultaneously. Showing positive results in pilot studies and animal models, ongoing clinical trials are carefully monitoring potential cardiac effects, such as on the qt interval, as it progresses through development.
Abstract
Ibogaine is a powerful psychoactive substance that not only alters perception, mood and affect, but also stops addictive behaviors. Ibogaine has a ...
A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats.
ACS chemical neuroscience – June 03, 2020
Summary
While known for anti-addictive properties, a single administration of the psychedelic drug ibogaine or its metabolite noribogaine remarkably showed antidepressant-like effects in a preclinical test. Researchers hypothesized these compounds could alleviate depression, observing rats after a single dose. Both ibogaine and noribogaine significantly reduced depression-like behaviors in a dose- and time-dependent manner. Interestingly, ibogaine’s positive effect persisted for hours, even when brain concentrations of both compounds were individually too low to act alone. This suggests a powerful combined action.
Abstract
Anecdotal reports and open-label case studies in humans indicated that the psychedelic alkaloid ibogaine exerts profound antiaddictive effects. Amp...
Can psychedelic compounds play a part in drug dependence therapy?
The British Journal of Psychiatry – January 01, 2015
Summary
After a 40-year hiatus, psychiatry is now revisiting psychedelic drug therapy for substance dependence. Hallucinogens like Psilocybin, Ayahuasca, and Ketamine are being examined. This medical shift, driven by potential patient improvements, underscores the importance of rigorous Psychedelics and Drug Studies. Psychotherapists are integral to these treatments, which involve complex Pharmacology and understanding Neurotransmitter Receptor Influence on Behavior. Despite clinical and legal limitations, the field of Psychology continues to advance, requiring careful Forensic Toxicology and Drug Analysis.
Abstract
Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psiloc...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Front Psychiatry – September 01, 2025
Summary
The brain's remarkable capacity to adapt and change is vital for mental well-being. Psychedelic therapy appears to harness this neuroplasticity, facilitating profound shifts in perception and thought. By exploring how these unique subjective experiences link to brain flexibility, positive clinical outcomes emerge. This offers a powerful avenue for improving mental health, promoting lasting therapeutic benefits.
Abstract
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Fearful symmetry in altered states: a bi-logic account of psychedelic action.
Front Psychol – August 19, 2025
Summary
Our minds often operate with two distinct, yet interacting, logical systems for processing information. A new theory proposes that psychedelics profoundly shift consciousness by altering the dynamic balance between these two fundamental modes of processing reality. Integrating neuroscientific and psychological insights, it suggests these substances don't just change perception, but enable a unique "bi-logic" state. This allows for novel perspectives and deep personal insights, potentially fostering significant psychological well-being and understanding.
Abstract
Fearful symmetry in altered states: a bi-logic account of psychedelic action.
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews.
Brain Sci – September 28, 2025
Summary
Emerging research highlights the surprising potential of psychedelics to effectively treat substance use disorders. A detailed synthesis of multiple systematic reviews explored this therapeutic avenue. The positive results consistently show these compounds can significantly reduce substance use and improve patient outcomes. This underscores a promising new direction for addiction treatment.
Abstract
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews.
Book Reviews : Psychedelic psychiatry: LSD from clinic to campus
Med Hist – October 01, 2010
Summary
LSD was once a promising psychiatric tool, not just a counterculture icon. A historical account traces its journey from clinical research to widespread societal impact. Early therapeutic applications showed remarkable potential for understanding and treating mental conditions. However, its eventual spread beyond medical settings led to complex cultural shifts. The narrative highlights the profound, multi-faceted influence of psychedelics on both medicine and society, inviting a fresh look at its legacy.
Abstract
Book Reviews : Psychedelic psychiatry: LSD from clinic to campus
Naturalism and the hard problem of mysticism in psychedelic science.
Front Psychol – March 15, 2024
Summary
Profound mystical experiences reported with psychedelics pose a unique challenge for science. Research explores how to integrate these deeply subjective states, which often feel transcendent, within a naturalistic scientific framework. It argues that understanding these powerful experiences doesn't require abandoning science, but rather expanding our view of consciousness. By examining the neural and psychological underpinnings, it shows that these transformative insights are real and can be understood, enriching our scientific comprehension of the mind.
Abstract
Naturalism and the hard problem of mysticism in psychedelic science.
Psychedelics in Psychiatry-Keeping the Renaissance From Going Off the Rails.
JAMA Psychiatry – May 01, 2021
Summary
Emerging evidence suggests psychedelics could revolutionize mental health treatment. A recent analysis explores their profound therapeutic potential, stressing the importance of establishing robust scientific and ethical guidelines. This approach is vital to responsibly integrate these powerful tools into psychiatry, ensuring their safe and effective use for lasting positive patient benefits.
Abstract
Psychedelics in Psychiatry-Keeping the Renaissance From Going Off the Rails.
Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.
Transl Psychiatry – November 13, 2025
Summary
Remarkably, psychedelics reshape our conscious experience by subtly altering brain activity. A comprehensive synthesis of studies on their chemical effects, brain imaging, and subjective impact revealed a powerful, interconnected process. It showed how these compounds induce measurable brain changes that underpin profound shifts in perception and mood. This integrated understanding offers valuable insights into consciousness and promising avenues for mental well-being.
Abstract
Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging ...
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
J Affect Disord – October 10, 2025
Summary
Accuracy in scientific reporting strengthens our understanding of emerging therapies. Previous research hypothesized a crucial role for the psychedelic experience in psilocybin treatment for severe depression. A recent correction refined specific data analysis details, reinforcing the initial finding that this unique experience is vital for its positive therapeutic effects. This ensures precise understanding of psilocybin's benefits for treatment-resistant depression.
Abstract
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders,...
Eigenmodes of the deep unconscious: The neuropsychology of Jungian archetypes and psychedelic experience.
PsyArXiv – October 20, 2024
Summary
The brain's deep patterns may explain universal human experiences. Research suggests Jungian archetypes, like hero or shadow, correspond to specific, fundamental patterns of brain activity. Using neuroimaging during psychedelic states, scientists observed distinct neural signatures aligning with reported archetypal encounters. This powerfully indicates a biological basis for these profound unconscious structures, offering new insights into consciousness.
Abstract
Eigenmodes of the deep unconscious: The neuropsychology of Jungian archetypes and psychedelic experience.
Psychiatric risks for worsened mental health after psychedelic use
PsyArXiv – October 17, 2023
Summary
Most people using psychedelics do not experience worsened mental health, but understanding specific risks is vital. A recent investigation explored how pre-existing conditions influence outcomes. It found that individuals with a history of certain psychiatric disorders, particularly psychosis or severe mood instability, faced a higher likelihood of experiencing worsened mental health symptoms. This crucial insight allows for better screening, ensuring these powerful compounds are safely and effectively applied for therapeutic benefit.
Abstract
Psychiatric risks for worsened mental health after psychedelic use
A mechanistic model of the neural entropy increase elicited by psychedelic drugs
Research Square – October 26, 2022
Summary
The profound shifts in consciousness from psychedelics stem from a dramatic increase in brain activity's complexity. A new model proposes these substances, by activating serotonin 2A receptors, disrupt normal brain signaling, creating more diverse neural patterns. Computational simulations successfully showed this mechanism generates the observed brain entropy increase. This offers a robust explanation for unique conscious states and highlights a promising pathway for new mental health treatments.
Abstract
A mechanistic model of the neural entropy increase elicited by psychedelic drugs
Self-blinding citizen science to explore psychedelic microdosing.
Elife – March 02, 2021
Summary
Could microdosing psychedelics subtly enhance daily life? A unique citizen science project explored this, with participants self-administering tiny, unknown doses or placebos to track effects on mood and cognition. Initial findings revealed participants often experienced improved mood, focus, and overall well-being. This innovative approach effectively gathered real-world data, highlighting microdosing's potential benefits.
Abstract
Self-blinding citizen science to explore psychedelic microdosing.
Updating the dynamic framework of thought: Creativity and psychedelics.
Neuroimage – March 08, 2020
Summary
Groundbreaking research suggests certain substances can significantly enhance the brain's ability to generate novel ideas. This research explores how **psychedelics** can positively influence our dynamic **thought processes**, thereby enhancing **creativity**. By analyzing their effects on neural and psychological functions, a new model reveals significant improvements in **cognitive flexibility** and divergent thinking, vital for innovative output. This offers valuable insights into human ingenuity.
Abstract
Updating the dynamic framework of thought: Creativity and psychedelics.